MetLife Investment Management LLC Lowers Stock Position in Boston Scientific Corporation $BSX

Key Points

• MetLife Investment Management LLC reduced its holdings in Boston Scientific Corporation by 1.9% to own 382,716 shares valued at approximately $38.6 million.
• Boston Scientific's stock received multiple upgrades, with price objectives raised by firms such as UBS Group to $135 and Wells Fargo to $124, indicating a strong positive outlook for the company.
• The company reported better-than-expected earnings, with $0.75 earnings per share for the last quarter, surpassing analysts' estimates of $0.72.

MetLife Investment Management LLC decreased its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 1.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 382,716 shares of the medical equipment provider's stock after selling 7,296 shares during the quarter. MetLife Investment Management LLC's holdings in Boston Scientific were worth $38,608,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. HM Payson & Co. increased its stake in shares of Boston Scientific by 1.4% in the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock valued at $694,000 after buying an additional 98 shares during the period. Baldwin Investment Management LLC raised its stake in Boston Scientific by 1.2% during the 4th quarter. Baldwin Investment Management LLC now owns 8,740 shares of the medical equipment provider's stock worth $781,000 after buying an additional 102 shares during the period. Park Square Financial Group LLC raised its stake in Boston Scientific by 5.2% during the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock worth $208,000 after buying an additional 103 shares during the period. HHM Wealth Advisors LLC boosted its stake in Boston Scientific by 13.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock valued at $89,000 after purchasing an additional 103 shares during the last quarter. Finally, Forum Financial Management LP boosted its stake in Boston Scientific by 0.8% during the 1st quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider's stock valued at $1,357,000 after purchasing an additional 112 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on BSX shares. Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Leerink Partners started coverage on shares of Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 target price on the stock. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Robert W. Baird lifted their target price on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Finally, Truist Financial lifted their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific currently has an average rating of "Buy" and an average price target of $117.50.

Boston Scientific Stock Performance

Shares of BSX stock traded up $1.31 during trading on Tuesday, reaching $106.42. 5,613,286 shares of the company's stock traded hands, compared to its average volume of 6,216,135. The company has a market capitalization of $157.69 billion, a P/E ratio of 63.35, a PEG ratio of 2.53 and a beta of 0.66. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The firm's 50-day moving average is $104.27 and its 200 day moving average is $102.15. Boston Scientific Corporation has a 1 year low of $79.03 and a 1 year high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. Boston Scientific's revenue was up 22.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 345,029 shares of company stock valued at $35,976,603 in the last quarter. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.